163 related articles for article (PubMed ID: 36863923)
1. [Current post-surgical treatment strategies in first-line ovarian cancer].
Ouali K; Michels J; Blanc-Durand F; Leary A; Kfoury M; Genestie C; Morice P; Zaccarini F; Scherrier S; Gouy S; Maulard A; Pautier P
Bull Cancer; 2024 Mar; 111(3):267-276. PubMed ID: 36863923
[TBL] [Abstract][Full Text] [Related]
2. Traitement médical de première ligne du cancer épithélial de l'ovaire de haut grade: First-line medical treatment of high-grade epithelial ovarian cancer.
Selle F; Alexandre J; Prulhière K; Kalbacher E; Ray-Coquard I; Leary A;
Bull Cancer; 2021 Dec; 108(9S1):S5-S12. PubMed ID: 34955161
[TBL] [Abstract][Full Text] [Related]
3. [Évolution des traitements adjuvants des cancers de l'ovaire].
Pautier P
Rev Prat; 2022 Jun; 72(6):633-637. PubMed ID: 35899664
[TBL] [Abstract][Full Text] [Related]
4. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
[TBL] [Abstract][Full Text] [Related]
5. First-Line Management of Advanced High-Grade Serous Ovarian Cancer.
Mahmood RD; Morgan RD; Edmondson RJ; Clamp AR; Jayson GC
Curr Oncol Rep; 2020 Jun; 22(6):64. PubMed ID: 32494876
[TBL] [Abstract][Full Text] [Related]
6. A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapy.
Zhang N; Zheng H; Gao Y; Shu T; Wang H; Cai Y
J Ovarian Res; 2024 Mar; 17(1):55. PubMed ID: 38444005
[TBL] [Abstract][Full Text] [Related]
7. Prise en charge médicale de la récidive du cancer épithélial de l'ovaire: Medical management of recurrent epithelial ovarian cancer.
Pautier P; Motte-Rouge T; Lécuru F; Classe JM; Ferron G; Floquet A; Kurtz JE; Freyer G; Hardy-Bessard AC
Bull Cancer; 2021 Dec; 108(9S1):S22-S32. PubMed ID: 34955159
[TBL] [Abstract][Full Text] [Related]
8. Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis.
Cheng H; Yang J; Liu H; Xiang Y
Arch Gynecol Obstet; 2021 Aug; 304(2):285-296. PubMed ID: 34021367
[TBL] [Abstract][Full Text] [Related]
9. AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial.
Heitz F; Marth C; Henry S; Reuss A; Cibula D; Gaba Garcia L; Colombo N; Schmalfeld B; de Gregorio N; Wimberger P; Hasenburg A; Sehouli J; Gropp-Meier M; Schouten PC; Hahnen E; Hauke J; Polleis S; Harter P
Int J Gynecol Cancer; 2023 Dec; 33(12):1966-1969. PubMed ID: 37935524
[TBL] [Abstract][Full Text] [Related]
10. Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon.
Abdallah R; Atallah D; Bitar N; Chahine G; Ghanem H; Ghosn M; Kattan J; Nasr F; Makdessi J; Shamseddine A
Gynecol Oncol Rep; 2023 Jun; 47():101186. PubMed ID: 37181681
[TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
[TBL] [Abstract][Full Text] [Related]
12. NIRVANA-1: maintenance therapy with niraparib versus niraparib-bevacizumab in patients with advanced ovarian cancer.
Sghaier S; Corbaux P; Ray-Coquard I; Lim MC; Hasegawa K; Nieuwenhuysen EV; Gonzalez A; Raspagliesi F; Freyer G
Future Oncol; 2023 Aug; 19(25):1715-1727. PubMed ID: 37650734
[TBL] [Abstract][Full Text] [Related]
13. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
Papa A; Caruso D; Strudel M; Tomao S; Tomao F
J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
[TBL] [Abstract][Full Text] [Related]
14. Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial).
Marth C; Abreu MH; Andersen KK; Aro KM; de Lurdes Batarda M; Boll D; Ekmann-Gade AW; Haltia UM; Hansen J; Haug AJ; Høgdall C; Korach J; Lassus H; Lindemann K; Van Nieuwenhuysen E; Ottevanger PB; Polterauer S; Schnack TH
Cancer; 2022 Aug; 128(16):3080-3089. PubMed ID: 35714310
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study.
Abe M; Shoji T; Chiba Y; Takatori E; Kaido Y; Nagasawa T; Kagabu M; Takahashi F; Aida T; Baba T
Anticancer Res; 2023 Mar; 43(3):1265-1272. PubMed ID: 36854492
[TBL] [Abstract][Full Text] [Related]
16. Maintenance therapy for newly diagnosed epithelial ovarian cancer- a review.
Nag S; Aggarwal S; Rauthan A; Warrier N
J Ovarian Res; 2022 Jul; 15(1):88. PubMed ID: 35902911
[TBL] [Abstract][Full Text] [Related]
17. [Not Available].
Joly F; Ray-Coquard I
Bull Cancer; 2021 Dec; 108(9S1):S1-S4. PubMed ID: 34955157
[TBL] [Abstract][Full Text] [Related]
18. FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer.
Arora S; Balasubramaniam S; Zhang H; Berman T; Narayan P; Suzman D; Bloomquist E; Tang S; Gong Y; Sridhara R; Turcu FR; Chatterjee D; Saritas-Yildirim B; Ghosh S; Philip R; Pathak A; Gao JJ; Amiri-Kordestani L; Pazdur R; Beaver JA
Oncologist; 2021 Jan; 26(1):e164-e172. PubMed ID: 33017510
[TBL] [Abstract][Full Text] [Related]
19. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Oza AM; Cook AD; Pfisterer J; Embleton A; Ledermann JA; Pujade-Lauraine E; Kristensen G; Carey MS; Beale P; Cervantes A; Park-Simon TW; Rustin G; Joly F; Mirza MR; Plante M; Quinn M; Poveda A; Jayson GC; Stark D; Swart AM; Farrelly L; Kaplan R; Parmar MK; Perren TJ;
Lancet Oncol; 2015 Aug; 16(8):928-36. PubMed ID: 26115797
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
Daniele G; Raspagliesi F; Scambia G; Pisano C; Colombo N; Frezzini S; Tognon G; Artioli G; Gadducci A; Lauria R; Ferrero A; Cinieri S; De Censi A; Breda E; Scollo P; De Giorgi U; Lissoni AA; Katsaros D; Lorusso D; Salutari V; Cecere SC; Zaccarelli E; Nardin M; Bogani G; Distefano M; Greggi S; Piccirillo MC; Fossati R; Giannone G; Arenare L; Gallo C; Perrone F; Pignata S
Int J Gynecol Cancer; 2021 Jun; 31(6):875-882. PubMed ID: 33931498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
